Detail akcie CytomX Therapeutics online

Business Summary: CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, CytomX Therapeutics Inc revenues increased 36% to $138.1M. Net income totaled $31.9M vs. loss of $569K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects oncology-focused biopharmaceutical segment income totaling $25M vs. loss of $6.5M, United States segment income totaling $25M vs. loss of $6.5M.